论文信息 - Altretamine in advanced pretreated epithelial ovarian carcinoma patients: Experience from a center in north India - 字舞流文

Altretamine in advanced pretreated epithelial ovarian carcinoma patients: Experience from a center in north India

D. Doval | Varun Goel | V. Talwar | N. Patnaik | S. Raina

[1] I. Vergote,et al. Altretamine (hexamethylmelamine) in the treatment of platinum-resistant ovarian cancer: a phase II study. , 2003, Gynecologic oncology.

[2] I. Malik. Altretamine is an effective palliative therapy of patients with recurrent epithelial ovarian cancer. , 2001, Japanese journal of clinical oncology.

[3] H. Ball,et al. Altretamine (hexamethylmelamine) in platinum-resistant and platinum-refractory ovarian cancer: a Gynecologic Oncology Group phase II trial. , 1998, Gynecologic oncology.

[4] J. Wharton. Hexamethylmelamine (altretamine) activity as a single agent in previously untreated advanced ovarian cancer. , 1991, Cancer Treatment Reviews.

[5] C. Cohen,et al. Hexamethylmelamine for the treatment of ovarian cancer--the Mount Sinai experience. , 1991, Cancer treatment reviews.

[6] D. Johnson,et al. A comparison of hexamethylmelamine (altretamine), cyclophosphamide, doxorubicin, and cisplatin (H-CAP) vs. cyclophosphamide, doxorubicin, and cisplatin (CAP) in advanced ovarian cancer. , 1991, Cancer treatment reviews.

[7] S. Marsoni,et al. Randomized comparison of hexamethylmelamine, adriamycin, cyclophosphamide (HAC) vs. cisplatin, adriamycin, cyclophosphamide (PAC) in advanced ovarian cancer: long-term results. , 1991, Cancer treatment reviews.

[8] L. Schwartz,et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.